{"title":"北印度儿童神经母细胞瘤的临床特征和预后：一项单中心回顾性研究","authors":"Zaibaish Khan, Nishant Verma","doi":"10.1016/j.phoj.2025.100466","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>With advances in pediatric oncology care, the outcome of children with neuroblastoma has improved. However, in low and middle-income countries (LMICs), the survival rate remains low. This study was conducted because of the paucity of data regarding the clinico-epidemiological profile and outcome of children with neuroblastoma in India.</div></div><div><h3>Methods</h3><div>Children (<13 y) with neuroblastoma treated at our centre between 2016 and 2022 were retrospectively analyzed.</div></div><div><h3>Results</h3><div>Over the 7-year study period, 53 children with neuroblastoma were treated at our centre. The age ranged from 1 month to 13 years (male: female ratio: 2.3:1). Adrenal was the most common primary site (58%). The majority of children had stage 4 disease (58.5%). The projected 2-year overall survival is 30%, whereas the event-free survival is 24.5%.</div></div><div><h3>Conclusions</h3><div>Children with neuroblastoma in our setting presented late with advanced disease. Even with a multidisciplinary approach, the survival rate for patients with advanced disease were still poor.</div></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"10 3","pages":"Article 100466"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical profile and outcome of children with Neuroblastoma: A single center retrospective study from North India\",\"authors\":\"Zaibaish Khan, Nishant Verma\",\"doi\":\"10.1016/j.phoj.2025.100466\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>With advances in pediatric oncology care, the outcome of children with neuroblastoma has improved. However, in low and middle-income countries (LMICs), the survival rate remains low. This study was conducted because of the paucity of data regarding the clinico-epidemiological profile and outcome of children with neuroblastoma in India.</div></div><div><h3>Methods</h3><div>Children (<13 y) with neuroblastoma treated at our centre between 2016 and 2022 were retrospectively analyzed.</div></div><div><h3>Results</h3><div>Over the 7-year study period, 53 children with neuroblastoma were treated at our centre. The age ranged from 1 month to 13 years (male: female ratio: 2.3:1). Adrenal was the most common primary site (58%). The majority of children had stage 4 disease (58.5%). The projected 2-year overall survival is 30%, whereas the event-free survival is 24.5%.</div></div><div><h3>Conclusions</h3><div>Children with neuroblastoma in our setting presented late with advanced disease. Even with a multidisciplinary approach, the survival rate for patients with advanced disease were still poor.</div></div>\",\"PeriodicalId\":101004,\"journal\":{\"name\":\"Pediatric Hematology Oncology Journal\",\"volume\":\"10 3\",\"pages\":\"Article 100466\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Hematology Oncology Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468124525000348\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology Oncology Journal","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468124525000348","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Clinical profile and outcome of children with Neuroblastoma: A single center retrospective study from North India
Background
With advances in pediatric oncology care, the outcome of children with neuroblastoma has improved. However, in low and middle-income countries (LMICs), the survival rate remains low. This study was conducted because of the paucity of data regarding the clinico-epidemiological profile and outcome of children with neuroblastoma in India.
Methods
Children (<13 y) with neuroblastoma treated at our centre between 2016 and 2022 were retrospectively analyzed.
Results
Over the 7-year study period, 53 children with neuroblastoma were treated at our centre. The age ranged from 1 month to 13 years (male: female ratio: 2.3:1). Adrenal was the most common primary site (58%). The majority of children had stage 4 disease (58.5%). The projected 2-year overall survival is 30%, whereas the event-free survival is 24.5%.
Conclusions
Children with neuroblastoma in our setting presented late with advanced disease. Even with a multidisciplinary approach, the survival rate for patients with advanced disease were still poor.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
